Background: The prevalence of hypertension with hyperuricemia varies between 22–38%, with 3–5 fold AZD8055 increased risk for coronary heart disease, peripheral arterial disease or cerebrovascular disease. Hypertension and hyperuricemia condition will trigger an increase in asymmetric dimethyl arginine (ADMA), decrease in nitric oxide and increase in reactive oxygen species, which in turn will lead to endothelial dysfunction. ARBs

losartan in hypertension therapy has the uricosuric agents, anti-inflammatory and antiagregation effects. Methods: The design of this study is a clinical trial before and after, which is done in general and consult policlinic, Internal Medicine Department at RSMH Palembang from May to August 2013. A total of 30 patients with stage 1 hypertension and hyperuricemia was given 50 mg losartan drug once daily for 8 weeks. Before therapy was started, blood pressure, serum uric acid, 24-hour urine uric acid and serum ADMA were measured and repeated after 8 weeks. Blood pressure was measured every 2 weeks. Results: The mean serum ADMA levels prior to administration of losartan was 0.74 μmol/l. The mean ADMA levels after the administration of losartan was 0.56 μmol/l. There was a decrease

in mean serum ADMA levels after the administration of losartan. The results were statistically significant on reduction of serum ADMA levels after the administration of losartan with P = 0.001. Conclusions: There is an influence of losartan on reduction of serum ADMA levels in hypertension patients with asymptomatic I BET 762 hyperuricemia, and the differences were statistically significant with P = 0.001. 220 RENAL RHEUMATOLOGY LUPUS VASCULITIS CLINIC – 4 YEARS EXPERIENCE G SINGH1, L WHITE2, P FLYNN2, S THOMAS2, L JEYASEELAN3, unless M THENMOZHI3, G JOHN2, P KUBLER2, D RANGANATHAN2 1Princess Alexandra Hospital, Brisbane, QLD; 2Royal Brisbane and Women’s Hospital,

Brisbane, QLD, Australia; 3Christian Medical College, Vellore, Tamil Nadu, India Aim: To measure the rate of progression of renal disease in patients who attend the Renal Rheumatology Lupus Vasculitis (RRLV) clinic and to compare the results to published studies in Lupus Nephritis (LN) and vasculitis. Background: Patients with connective tissue disorder have multisystem involvement and attend Rheumatology and other sub speciality clinics including Nephrology. In July 2009 a combined RRLV clinic, probably first of its kind for adult patients in Australia, was implemented at Royal Brisbane & Women’s Hospital. Studies have shown patient survival rates at 5 and 10 years for vasculitis patients are 83% and 74% and for LN patients are 88% and 77% respectively. We compared outcome data for patients followed up in our clinic to published studies. Methods: This analysis is a retrospective chart audit of all the patients who attended this clinic from July 2009 to October 2013.